摘要

The use of antiangiogenic drugs, besides chemotherapy, is a cornerstone for the treatment of epithelial ovarian cancer and is highly recommended in 2014. This review of the literature on this topic focuses on the most outstanding clinical trial results in which a number of drugs have been tested in France and worldwide, whereas only bevacizumab is, so far, approved. We review the major antiangiogenic drugs that have been investigated in epithelial ovarian cancer, and discuss, the forthcoming situation where multiple and relatively similar drugs will be challenging each other at all stages of the disease.

  • 出版日期2014-6

全文